Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week.
- BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week.
- This prominent event, organized by the United European Gastroenterology and scheduled to take place in Copenhagen, Denmark, from October 14th to 17th, serves as a premier platform for discussing the latest advancements and breakthroughs in the field of gastroenterology.
- Recognized as a key gathering in the field, UEG Week addresses critical issues in gastroenterology, providing an ideal opportunity for Mainz Biomed to engage with international gastroenterologists, oncologists, and stakeholders interested in advancing the early detection of colorectal cancer (CRC).
- Mainz Biomed team members will be available throughout the event showcasing ColoAlert® the Company’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer (CRC).